| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Joan Brunet | Q37378402 |
| Javier A Menendez | Q56503568 | ||
| P2093 | author name string | Ramon Colomer | |
| Alejandro Vazquez-Martin | |||
| Rafael De Llorens | |||
| Laura Ferrer-Soler | |||
| P433 | issue | 1 | |
| P304 | page(s) | 3-10 | |
| P577 | publication date | 2007-07-01 | |
| P1433 | published in | International Journal of Molecular Medicine | Q6051492 |
| P1476 | title | An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review) | |
| P478 | volume | 20 |
| Q35111697 | A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network |
| Q37665524 | A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer |
| Q37109741 | A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth |
| Q33476095 | A site-specific, multiplexed kinase activity assay using stable-isotope dilution and high-resolution mass spectrometry |
| Q35012485 | Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib |
| Q35058437 | Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases |
| Q58703557 | Anti‑breast cancer activity of selected 1,3,5‑triazines via modulation of EGFR‑TK |
| Q37613072 | Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors |
| Q34919815 | Development of an epidermal growth factor derivative with EGFR blocking activity |
| Q45860878 | Dysregulation of POPDC1 promotes breast cancer cell migration and proliferation |
| Q36250585 | Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence |
| Q39619637 | Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells |
| Q24296333 | FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice |
| Q34855692 | Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer |
| Q36545398 | Heregulin, a new interactor of the telosome/shelterin complex in human telomeres. |
| Q37676970 | Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function |
| Q36245418 | Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells. |
| Q39799281 | Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response |
| Q39940485 | Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. |
| Q49887925 | Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges |
| Q36330264 | Research progress on criteria for discontinuation of EGFR inhibitor therapy |
| Q52686152 | Revisiting the IGF-1R as a breast cancer target. |
| Q34005061 | Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands |
| Q92372864 | Targeting Degradation of EGFR through the Allosteric Site Leads to Cancer Cell Detachment-Promoted Death |
| Q63447350 | Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer |
| Q35889618 | Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer |
| Q37135372 | The ERBB3 receptor in cancer and cancer gene therapy |
| Q37006174 | The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies |
| Q39991646 | The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia |
| Q38322924 | Thirty years of intracrinology |
| Q36458755 | Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited? |
| Q41592800 | siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells |
Search more.